Navigation Links
Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations
Date:2/25/2008

FRANKFURT, Germany, February 25 /PRNewswire/ -- t2cure, a clinical stage biopharmaceutical company developing novel regenerative therapies based on autologous progenitor cells, announced today that it has appointed Dr. Petra Rueck Head of Clinical Operations.

"We are pleased to have Petra join our company", said Manfred Ruediger, CEO of t2cure. "Petra's experience in clinical research and project management will be of critical importance to t2cure as we are preparing to move our lead product into Phase III clinical trials for severe infarcts."

"It is a unique opportunity to contribute to the development of therapies that have the potential to significantly improve patient outcomes", said Petra Rueck. "t2cure's clinical candidates have demonstrated their capacity to increase the regenerative potential of tissue damaged by acute myocardial infarctions and other cardiac or peripheral vascular diseases."

Prior to joining t2cure, Dr Rueck was a project leader with ratiopharm's Biogenerix AG, Mannheim, where most recently she was responsible for a biotechnology project including the design and management of preclinical and clinical development programs. Her previous experience includes positions in clinical research management at Pfizer and Intervet. Before that, Dr. Rueck was assistant professor at Berlin University Hospital "Benjamin Franklin" (now Charite) and worked as postdoctoral researcher at INSERM, Paris. Petra Rueck received her PhD degree in pharmacology from the University of Giessen, Germany, where she studied veterinary medicine.

About t2cure GmbH

t2cure GmbH is a biopharmaceutical company engaged in the field of stem cell-based regenerative medicine. It develops autologous bone marrow-derived progenitor cells as regenerative therapeutics for cardiovascular disease including ischemic heart disease (acute myocardial infarction and chronic ischemic heart disease, non-ischemic heart failure, peripheral arterial occlusiv
'/>"/>

SOURCE t2cure GmbH
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. National Stem Cell Holding, Inc. Has Engaged BMA Securities to Assist and Advise the Company With Its Current Capital Raise of $3,500,000
2. European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions
3. Nastech Pharmaceutical Company Implements Additional Workforce Reduction as Part of Previously Announced Corporate Restructuring
4. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
5. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
6. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
7. LS9, Inc., the Renewable Petroleum Company(TM), Adds Key Positions to Executive Team and Scientific Advisory Board
8. Perrigo Company to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Halogen Receives High Ratings from Bersin & Associates - Company recognized as a market leader, and receives praise for outstanding customer satisfaction
10. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
11. Kiwa Bio-Tech Products Group Discusses Cooperative Efforts With Canadian Agricultural Ministry and Canadian Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to announce that ... an e-Journal and producer of Food Labs Conference ... for the co-location of Food Labs Conference to be held ... registration fee to attend the two-day Food Lab Conference, March ...
(Date:1/15/2014)... 2014 Look inside the new Preferred ... the lab, from fluid handling to instruments to supplies. ... when you order. , Preferred Solutions features a ... the L/S® model for precise flow control and dispensing ...
(Date:1/15/2014)... California , January 15, 2014 Oxford ... today announced the appointment of Thomas C Reynolds MD, PhD ... years, development experience gained in the biotechnology industry, most recently ... am delighted to welcome Tom at this transformative time for ...
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... out of the bottle isnt always easy. However, shaking the ... to flow more freely because it becomes more fluid when ... such as water does not become a gel when shaken. ... issue of the journal Physical Review Letters shows that when ...
... 30 InterMune, Inc.,(Nasdaq: ITMN ) today announced ... of InterMune, will present at the Deutsche Bank,33rd Annual ... at 4:10 p.m.,EDT., To access a live audio ... log on to the investor relations page of InterMune,s,corporate ...
... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced its ... ended March 31, 2008., "We are currently ... nine,clinical trials, four exploring the use of REOLYSIN(R) ... REOLYSIN(R) in combination with a variety of,chemotherapies, immune ...
Cached Biology Technology:Atomic force microscopy reveals liquids adjust viscosity when confined, shaken 2Atomic force microscopy reveals liquids adjust viscosity when confined, shaken 3Oncolytics Biotech Inc. Announces 2008 First Quarter Results 2Oncolytics Biotech Inc. Announces 2008 First Quarter Results 3Oncolytics Biotech Inc. Announces 2008 First Quarter Results 4Oncolytics Biotech Inc. Announces 2008 First Quarter Results 5Oncolytics Biotech Inc. Announces 2008 First Quarter Results 6Oncolytics Biotech Inc. Announces 2008 First Quarter Results 7Oncolytics Biotech Inc. Announces 2008 First Quarter Results 8Oncolytics Biotech Inc. Announces 2008 First Quarter Results 9Oncolytics Biotech Inc. Announces 2008 First Quarter Results 10Oncolytics Biotech Inc. Announces 2008 First Quarter Results 11Oncolytics Biotech Inc. Announces 2008 First Quarter Results 12Oncolytics Biotech Inc. Announces 2008 First Quarter Results 13Oncolytics Biotech Inc. Announces 2008 First Quarter Results 14Oncolytics Biotech Inc. Announces 2008 First Quarter Results 15Oncolytics Biotech Inc. Announces 2008 First Quarter Results 16Oncolytics Biotech Inc. Announces 2008 First Quarter Results 17Oncolytics Biotech Inc. Announces 2008 First Quarter Results 18Oncolytics Biotech Inc. Announces 2008 First Quarter Results 19Oncolytics Biotech Inc. Announces 2008 First Quarter Results 20Oncolytics Biotech Inc. Announces 2008 First Quarter Results 21Oncolytics Biotech Inc. Announces 2008 First Quarter Results 22Oncolytics Biotech Inc. Announces 2008 First Quarter Results 23Oncolytics Biotech Inc. Announces 2008 First Quarter Results 24Oncolytics Biotech Inc. Announces 2008 First Quarter Results 25Oncolytics Biotech Inc. Announces 2008 First Quarter Results 26Oncolytics Biotech Inc. Announces 2008 First Quarter Results 27Oncolytics Biotech Inc. Announces 2008 First Quarter Results 28Oncolytics Biotech Inc. Announces 2008 First Quarter Results 29Oncolytics Biotech Inc. Announces 2008 First Quarter Results 30Oncolytics Biotech Inc. Announces 2008 First Quarter Results 31Oncolytics Biotech Inc. Announces 2008 First Quarter Results 32Oncolytics Biotech Inc. Announces 2008 First Quarter Results 33
(Date:4/22/2014)... This news release is available in French . ... less than a month, sequencing of the complete genome ... in Guinea forms a clade (variant) that is distinct ... Congo and in Gabon. Epidemiological investigations also linked the ... the December 2013 outbreak. , Ebola virus is a ...
(Date:4/22/2014)... not only on weight loss but also on diabetes ... University of Cincinnati have shown that the health benefits ... size but by increased levels of bile acids in ... indicate that bile acids could be a new target ... the Sahlgrenska Academy has demonstrated that obesity surgery is ...
(Date:4/21/2014)... from dairy cows, which is commonly used as a ... identified antibiotic resistance genes from the cows, gut bacteria. ... open-access journal of the American Society for Microbiology, hints ... types of antibiotic resistance genes that transfer to bacteria ... Thousands of antibiotic resistance (AR) genes have already been ...
Breaking Biology News(10 mins):Inserm and the Institut Pasteur identify a new variant of Ebola virus in Guinea 2Researchers identify a mechanism linking bariatric surgery to health benefits 2Cow manure harbors diverse new antibiotic resistance genes 2Cow manure harbors diverse new antibiotic resistance genes 3
... skies and smooth sailing for oceanic vessels has been ... air pollution and greenhouse gas emissions that impact the ... Winebrake and James Corbett examines "Emission Tradeoffs among Alternative ... Marine Gas Oil, and Marine Diesel Oil," in a ...
... the way you expect, take a closer look -- something ... scientists at the U.S. Department of Energy,s (DOE) Brookhaven National ... that could help expand the toolbox for engineering biofuels and ... the week of September 8, 2008, in the Proceedings ...
... The U.S. Department of Energy Joint Genome Institute ... Integrated Microbial Genomes (IMG) data management system, updated ... and analysis system, and has launched its educational ... includes new microbial genomes from Version 29 release ...
Cached Biology News:Fuel emissions from marine vessels remain a global concern 2Enzyme detectives uncover new reactions, products 2Enzyme detectives uncover new reactions, products 3DOE JGI extends the capabilities of the Integrated Microbial Genome System 2DOE JGI extends the capabilities of the Integrated Microbial Genome System 3
... solution is a highly scalable analysis ... data in a workgroup or an ... over 40 leading pharmaceutical, biotechnology, academic ... Workgroup streamlines genomics research at large ...
... scale kinase profiling, quantitative measurement of ... research built on the flexible and ... These microarrays are available as part ... - Peptide Microarray Service. ...
... is an 18 amino acid synthetic peptide whose sequences are derived ... (amino to carboxy terminus): S(21) - S - M - P ... E - A - I - D - K - K ... This peptide may be used for neutralization and control experiments ...
... built on the flexible and powerful ... microarrays are available as part of ... Custom Probe Content ... Thousands of customer specified peptide sequences ...
Biology Products: